COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISORDERS, COMPRISING BEE VENOM EXTRACT AS ACTIVE INGREDIENT

The present invention relates to a composition for preventing or treating neuroinflammatory disorders, comprising a bee venom extract as an active ingredient. More specifically, the present invention provides a pharmaceutical composition or a health functional food composition for preventing or trea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	RHEE, Hae In, KIM, Kuk Hyun
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a composition for preventing or treating neuroinflammatory disorders, comprising a bee venom extract as an active ingredient. More specifically, the present invention provides a pharmaceutical composition or a health functional food composition for preventing or treating neuroinflammatory disorders, both of which comprise, as an active ingredient, a bee venom extract in which the amount of phospholipase A2 (PLA2) is 50 to 85%. The bee venom extract alleviates decreased motor functions caused by neurotoxicity and has neuroprotective and neuroinflammation-relieving effects, thereby enabling the prevention or treatment of neuroinflammatory disorders. Particularly, a pharmaceutical composition according to the present invention can further improve an effect of preventing or treating neuroinflammatory disorders by being subcutaneously administered or by being co-administered with a STAT3 inhibitor or an NF-κB inhibitor, thereby enabling more effective prevention or treatment of neuroinflammatory disorders.